U.S. markets close in 3 hours 33 minutes
  • S&P 500

    4,365.54
    -77.57 (-1.75%)
     
  • Dow 30

    34,410.93
    -458.44 (-1.31%)
     
  • Nasdaq

    14,622.15
    -347.82 (-2.32%)
     
  • Russell 2000

    2,241.69
    -39.31 (-1.72%)
     
  • Crude Oil

    75.03
    -0.42 (-0.56%)
     
  • Gold

    1,738.40
    -13.60 (-0.78%)
     
  • Silver

    22.48
    -0.21 (-0.94%)
     
  • EUR/USD

    1.1692
    -0.0010 (-0.08%)
     
  • 10-Yr Bond

    1.5250
    +0.0410 (+2.76%)
     
  • GBP/USD

    1.3545
    -0.0159 (-1.16%)
     
  • USD/JPY

    111.3760
    +0.3980 (+0.36%)
     
  • BTC-USD

    41,625.70
    -1,626.06 (-3.76%)
     
  • CMC Crypto 200

    1,030.92
    -26.22 (-2.48%)
     
  • FTSE 100

    7,028.10
    -35.30 (-0.50%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RedHill Biopharma RDHL announced data from a preclinical in vivo study, evaluating its COVID-19 drug Opaganib in kidney inflammation and fibrosis. Data from the study demonstrated that Opaganib achieved efficacy in significantly reducing renal fibrosis in patients with chronic kidney disease (“CKD”) in a well characterized unilateral ureteral obstruction model.

Shares of RedHill have rallied 18.2% so far this year against the industry’s 9.6% decline.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

In CKD patients, renal fibrosis is a progressive process that may result in end-stage renal failure. COVID-19 and long COVID patients also have a high risk of kidney damage.

More than 20% of hospitalized COVID patients experience acute renal failure. Acute kidney injury –- a potential consequence of COVID-19 –- results in the inability of the kidneys to be repaired properly. Opaganib inhibits the sphingosine kinase-2, a key enzyme that is part of the process that prevents the kidney from repairing itself and replicating the COVID-19 virus.

It is to be noted that Opaganib, an oral pill drug candidate with dual anti-inflammatory and antiviral activity, is currently being evaluated in a phase II/III study in hospitalized patients with COVID-19. This study has completed treatment and follow up phase, with top-line results expected shortly.

The company recently announced positive preliminary results from a new preclinical study on Opaganib. The drug demonstrated strong inhibition of delta variant of the COVID virus in a human bronchial epithelial cells model, adding to prior data demonstrating potent inhibition of all COVID-19 variants tested to date.

Redhill Biopharma Ltd. Price

Redhill Biopharma Ltd. Price
Redhill Biopharma Ltd. Price

Redhill Biopharma Ltd. price | Redhill Biopharma Ltd. Quote

Zacks Rank & Stocks to Consider

RedHill currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the biotech/drug sector include Ironwood Pharmaceuticals IRWD, Regeneron Pharmaceuticals REGN and Repligen Corporation RGEN, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Ironwood’s earnings per share estimates for 2021 have increased from $1.00 to $1.18 in the past 60 days. The same for 2022 has risen from $1.18 to $1.72 over the same period. The stock has rallied 10.3% in the year so far.

Regeneron’s earnings per share estimates for 2021 have increased from $49.51 to $54.15 in the past 60 days. The same for 2022 has risen from $41.30 to $44.11 over the same period. The stock has rallied 38.4% in the year so far.

Repligen’s earnings per share estimates for 2021 have increased from $2.26 to $2.76 in the past 60 days. The same for 2022 has risen from $2.56 to $3.02 over the same period. The stock has rallied 54.6% in the year so far.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report

Repligen Corporation (RGEN) : Free Stock Analysis Report

Redhill Biopharma Ltd. (RDHL) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research